Table 3 Estimated annual GP, specialist and liver ultrasound appointments required in year 4 of the program and sensitivity analysis of incremental service utilisation, compared to baseline (no program)
Treatment group | Number of people* | Annual appointments related to CHB surveillance and/or treatment | ||
|---|---|---|---|---|
| Â | Â | GP appointments (averaged per GP) | Specialist (averaged per specialist) | Ultrasound |
Routine Surveillance (GP-led) | 745 | 1,303 | Â | Â |
Enhanced Surveillance (GP-led) | 263 | 460 | Â | 263 |
Interferon (Specialist-led) | 8 | Â | 44 | 7 |
Entecavir (Specialist-led) | 201 | Â | 781 | 195 |
Other** | 236 | Â | 18 | 8 |
Total cohort | 1,452 | 1,763 | 843 | 473 |
Baseline (no program) | 1,452 | 28 | 84 | 54 |
Incremental service utilisation (over no program) | ||||
   At 25% program uptake | 0 | 1,734 (5.0) | 759 (25.3) | 419 |
   At 10% program uptake | 0 | 694 (2.0) | 304 (10.1) | 167 |
   At 65% program uptake | 2 | 4,509 (12.9) | 1,974 (65.8) | 1,089 |
With viral load cut-off of 2000 IU/ml at all ages in program | 0 | 1,648 (4.7) | 961 (32.0) | 557 |
If ALT cut-off varies, so 20% have high ALT | 0 | 1,908 (5.5) | 274 (9.1) | 380 |
If ALT cut-off varies, so 90% have high ALT | 0 | 1,475 (4.2) | 1,370 (45.7) | 427 |
If age at enrolment is ≥ 40 years (instead of 35) | 0 | 1,327 (3.8) | 616 (20.5) | 344 |